Credit: Shutterstock photoWhen considering what names to put on your watch list, look for stocks with an 80 or higher RS Rating . Pacira Pharmaceuticals ( PCRX ) just met that criteria with a new score of 81.
[ibd-display-video id=2881825 width=50 float=left autostart=true] IBD's unique RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks matches up against the rest of the market.
Decades of market research shows that the top-performing stocks typically have an RS Rating north of 80 as they launch their biggest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock goes on to form a chart pattern and break out.
In terms of top and bottom line numbers, the company has posted two quarters of rising earnings growth. Revenue growth has been less impressive, coming in at -1% in the most recent quarterly report.
Pacira Pharmaceuticals holds the No. 129 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics ( CORT ), Sucampo Pharmaceuticals ( SCMP ) and Xoma ( XOMA ) are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
